Vaitarana Basti and Shatpushpadi lepa in Arthritis (Amavata)

Not yet recruiting

• Conditions: Rheumatoid arthritis with rheumatoid factor, unspecified. Ayurveda Condition: AMAVATAH,

• Registration Number: CTRI/2023/07/055850
• Lead Sponsor: Rishikul Campus

Brief Summary

Amavata is progressive sporadic disorder found in general population with complaints of doing routine work due to dysfunction of joints. Amavata was first expained in Madhav Nidana.  Clinical presentation of Pravriddha Amavata closely resembles with Rheumatoid arthritis which is chronic multisystem disease of unknown cause. The characteristic feature of RA are persistent inflammatory synovitis, usually involving peripheral joints in symmetrical distributions. Now a days rheumatoid arthritis is more common and distressing among all joints problems. The prevalence of rheumatoid arthritis in worldwide is 0.8% and in India it is 0.7%.

Patients of amavata presents with complaints of angamarda, aruchi, trishna, gaurava along with complaints of sandhishoola, sandigraha and sandhisotha. Symptoms of RA  includes pain and swelling in affected joints and morning stifness.

The therapy chosen for this study is Vaitarana basti in comparison with Shatpushpadi lepa. Vaitarana basti is mentioned in Chakradutta and is said to having shoola, anaha and amavatahara properties. Shatpushpadi lepa is mentioned in Yogratanakara. Lepa contols doshas at localized level and offers instant relief as skin provides large surface area and is easy to use.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-07-15
• Study Start: 2023-07-30

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Patients having sign and symptoms of Amavata (Rheumatoid arthritis).
• Patients of age between 20 years to 50 years will be included.
• Patients with less than 5 years of chronicity.
• Patients able to participate in study and ready to follow the instruction.

Exclusion Criteria

• Patients with joint deformity.
• 2.Uncontrolled diabetes mellitus, Hypertension & life threatening disease.
• Patients having dermatomyositis, scleroderma, acute rheumatic fever , gouty arthritis.
• Patients having Skin allergy and hypersensitivity.
• Pregnant and lactating women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complete remission: 100%	0th, 30th, 60th day
Marked improvement: 75%	0th, 30th, 60th day
Moderate improvement: 51%-75%	0th, 30th, 60th day
Mild improvement: 26%-50%	0th, 30th, 60th day
No improvement: 0-25%	0th, 30th, 60th day

Secondary Outcome Measures

Name	Time	Method
Exacerbation in sign & symptoms	60 days

Trial Locations

Locations (1)

Rishikul campus, UAU, Haridwar; 🇮🇳 Hardwar, UTTARANCHAL, India

Rishikul campus, UAU, Haridwar

🇮🇳Hardwar, UTTARANCHAL, India

DrSanjna Sharma

Principal investigator

8557904727

superbsanjna@gmail.com